Dysgeusia News and Research

RSS
Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Chantix new quit smoking drug approved

Chantix new quit smoking drug approved